Annovis Bio (ANVS) Current Assets (2019 - 2024)
Annovis Bio (ANVS) posted Current Assets of $7.8 million for Q1 2024, down 23.46% sequentially from $10.2 million in Q4 2023, and down 69.42% YoY from $25.5 million in Q2 2023.
Annovis Bio (ANVS) Current Assets (2019 - 2024) Analysis & Trends
Annovis Bio has reported Current Assets for 6 years, with the latest figure at $7.8 million in Q1 2024.
- Quarterly Current Assets fell 69.42% year-over-year to $7.8 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $7.8 million (down 69.42% YoY) and the FY2023 annual result came in at $10.2 million, down 71.66% from the prior year.
- Current Assets retreated to $7.8 million in Q1 2024 per ANVS's latest filing, from $10.2 million in the prior quarter.
- Over five years, Current Assets peaked at $49.5 million in Q2 2021 and troughed at $6.0 million in Q1 2021.
- A 5-year average of $24.8 million and a median of $22.8 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2020 and 2023: Current Assets surged 986.18% in 2020, then tumbled 72.46% in 2023.
- Over 5 years, Current Assets stood at $8.1 million in 2020, then surged by 466.57% to $46.0 million in 2021, then declined by 21.69% to $36.0 million in 2022, then slumped by 71.66% to $10.2 million in 2023, then fell by 23.46% to $7.8 million in 2024.
- According to Business Quant data, Current Assets over the past three periods registered $7.8 million, $10.2 million, and $10.2 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Annovis Bio | 66.78 Mn | 66.78 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 7.81 Mn |
| Dec 31, 2023 | 10.21 Mn |
| Sep 30, 2023 | 10.22 Mn |
| Jun 30, 2023 | 22.82 Mn |
| Mar 31, 2023 | 25.55 Mn |
| Dec 31, 2022 | 36.02 Mn |
| Sep 30, 2022 | 37.12 Mn |
| Jun 30, 2022 | 39.97 Mn |
| Mar 31, 2022 | 44.10 Mn |
| Dec 31, 2021 | 46.00 Mn |
| Sep 30, 2021 | 47.65 Mn |
| Jun 30, 2021 | 49.50 Mn |
| Mar 31, 2021 | 5.96 Mn |
| Dec 31, 2020 | 8.12 Mn |
| Sep 30, 2020 | 9.40 Mn |
| Jun 30, 2020 | 10.20 Mn |
| Mar 31, 2020 | 11.44 Mn |
| Dec 31, 2019 | 747,512.00 |